Table 1: Characteristics of obese patients with diabetes mellitus type 1 during weight reduction programme

From: Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction

 Phase IPhase IIPhase IIISig. I vs IISig. I vs III
BMI (kg m−2)33.2 (32.4; 33.6)31.5 (30.4; 32.2)32.7 (31.6; 32.9)*P<0.001*P<0.001
Waist circumference (cm)108 (105; 110)103 (94; 106)105 (92; 110)*P<0.001*P<0.05
HbA1c (%, IFCC)5.8 (5.5; 6.6)5.7 (5.1; 6.2)6.6 (6.1; 6.9)NS*P<0.05
Insulin per day (IU)50.0 (39.3; 54.0)37.5 (32; 40.3)42.0 (39.3; 51.0)*P<0.001*P<0.001
Relative fat tissue mass (%)36 (33.3; 37.8)34.7 (32.7; 38.1)34.3 (33.8; 34.9)NSNS
Relative lean tissue mass (%)49.4 (43.1; 58.9)53.4 (47.6; 54.8)51.5 (49.6; 53.5)NSNS
Fat tissue index (kg m−2)16.1 (14.8; 16.9)14.4 (13.5; 15.7)15.3 (14.1; 17.8)*P<0.05NS
Total cholesterol (mmol l−1)4.95 (4.39; 5.57)4.10 (3.88; 5.03)4.91 (4.28; 5.47)*P<0.05NS
HDL cholesterol (mmol l−1)1.30 (0.97; 1.59)1.14 (1.03; 1.39)1.49 (1.15; 2.01)NS*P<0.05
LDL cholesterol (mmol l−1)3.35 (2.3; 3.7)2.45 (2.02; 3.23)2.71 (2.24; 3.11)*P<0.05NS
Triacylglycerols (mmol l−1)1.28 (1.03; 1.59)1.04 (0.91; 1.68)0.83 (0.63; 1.41)NSNS
Free fatty acids (mmol l−1)0.52 (0.35; 0.59)0.40 (36; 0.68)0.43 (0.29; 0.60)NS*P<0.05
Squalene (μmol l−1)2.05 (1.23; 2.41)2.09 (1.80; 2.51)1.49 (0.60; 2.84)NSNS
Lathosterol (μmol l−1)8.15 (6.46; 10.25)9.37 (7.55; 9.80)5.44 (2.44; 6.09)NSP<0.001
Campesterol (μmol l−1)13.53 (7.96; 16.46)8.46 (6.22; 11.76)5.68 (4.15; 7.53)*P<0.05*P<0.05
Sitosterol (μmol l−1)8.08 (6.87; 11.76)5.66 (4.61; 9.51)7.42 (4.24; 8.70)*P<0.05NS
Lathosterol/cholesterol (μmol l−1 mmol l−1)1.45 (1.28; 2.25)1.82 (1.41; 2.37)0.99 (0.53; 1.36)*P<0.05*P<0.05
Campesterol/cholesterol (μmol l−1 mmol l−1)2.48 (1.56; 3.49)1.88 (1.75; 2.89)1.10 (0.95; 1.37)*P<0.05P<0.001
β-Sitosterol/cholesterol (μmol l−1 mmol l−1)1.77 (1.01; 2.12)1.48 (0.98; 1.75)1.46 (0.87; 1.97)NSNS
Omentin (ng ml−1)5.31 (3.72; 6.49)5.05 (3.91; 7.32)9.74 (9.11; 10.98)NSP<0.001
  1. Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HbA1c, glycated haemoglobin; IFCC, International Federation of Clinical Chemistry; LDL, low-density lipoprotein; NS, non-significant; phase I, before weight reduction programme; phase II, after a month of weight reduction programme; phase III, after 12 months of weight reduction programme; Sig. I vs II, III, significance among phases I, II or III. *P, significant (P-value).